Zeo Scientifix, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OQB
Zeo ScientifiX, Inc. announced a significant increase in revenue for the second quarter of fiscal year 2026, driven by strong performance in its allogenic biologic products.
OQB
Zeo ScientifiX reported a 32.7% revenue increase and reduced net loss, but continues to face substantial doubt about its ability to continue as a going concern amidst regulatory and legal challenges.
OQB
Zeo ScientifiX reported a significantly wider net loss and expressed substantial doubt about its ability to continue as a going concern, despite revenue growth from its PPX service platform.
OQB
Zeo ScientifiX, a clinical-stage biopharmaceutical company, reported an increased net loss for the six months ended April 30, 2025, alongside a significant going concern warning and shifts in product revenue streams.
OQB
Zeo ScientifiX's Q1 2025 revenue decreased slightly due to lower biologic product sales, offset by growth in its PPX service platform.
OQB
Zeo ScientifiX reported a net loss of $1.012 million for the third quarter of 2024, with a decrease in revenue and ongoing concerns about its ability to continue as a going concern.
OQB
10-Q: Zeo ScientifiX Reports Increased Revenue but Continues to Face Going Concern Challenges in Q2 2024
Zeo ScientifiX saw a revenue increase in Q2 2024, but ongoing losses and a working capital deficit raise concerns about the company's ability to continue as a going concern.
OQB
Zeo ScientifiX, formerly Organicell Regenerative Medicine, saw a revenue increase and a reduction in net losses for the first quarter of 2024 compared to the same period last year.